CytomX raises $30M via private placement of units with warrants

CytomX Therapeutics, Inc.

Gross proceeds of $30M from unit sale at $2.08 each; closing expected July 3, 2023.
Each unit: 1 share or Pre-Funded Warrant ($0.00001 exercise, 20-yr term) plus Tranche 1 ($4.16, exp. 2025) and Tranche 2 ($6.24, exp. 2026) warrants.
No underwriter; resale registration statement to be filed within 60 days after closing.
Pre-funded and Tranche warrants may not be exercised if holder would exceed 9.99% ownership (adjustable to 19.99%).
Exercise price of Tranche warrants subject to reset if future offering below $4.16, but not below $2.08.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CytomX Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $30.0 million (effective 2023-06-29).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $30.0 million
Effective: 2023-06-29

Exact text from the filing

On June 29, 2023, CytomX Therapeutics, Inc. (the “Company”) entered into a unit purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”).

View on SEC.gov

Browse all material agreements →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-180722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.